 JMP Securities has initiated the coverage on Aura Biosciences Inc NASDAQ: AURA with a Market Outperform rating and a 26 risk-adjusted price target. Aura is developing a targeted virus-like drug conjugate VDC technology platform that could establish a new standard of. 